Francesca Scala

Francesca Scala

Auto-generated profile, based on publicly available information

Francesca Scala

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy; PhD Program in Drug Discovery and Development, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
EGErica Gazzillo
Erica Gazzillo
LCLucia Capasso
Lucia Capasso
FSFrancesca Scala
Francesca Scala
MAMichela Aliberti
Michela Aliberti
ACAlessandra Capuano
Alessandra Capuano
GBGiuseppe Bifulco
Giuseppe Bifulco
The intrinsically disordered protein (IDP) c-Myc plays a crucial role in regulating cell growth, proliferation, and apoptosis, making it a significant target for cancer therapy. Herein, we report an integrated approach combining computational and biological methods to uncover key c-Myc structural aspects aimed at identifying modulators of this protein. A virtual screening campaign starting from commercially available libraries was performed, leading to the selection of 11 promising c-Myc binders. Preliminary biophysical and biological analysis, including Surface Plasmon Resonance (SPR) and MTT [(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide)] assays, highlighted three new potential c-Myc/Max heterodimerization inhibitors. Among them, 11 emerged as the most active one, displaying promising dissociation costant (KD) values on c-Myc (~ 60 μM), only slightly higher than the known binder 10058-F4 (with a KD ~ 40 μM) and on Max (with a KD ~ 80 μM). Notably, 11 showed significant antiproliferative effects on three different malignant cell lines (i.e., U937, HCT-116, and HT-29, as models of acute myeloid leukemia and colorectal cancer cell lines, respectively) in a dose- and cell-dependent manner. Importantly, a significant decrease in c-Myc levels was observed, especially in U937 leukemia cells with an 85 % reduction. Finally, molecular dynamics simulations and proteomic studies were performed to identify its binding site and key interacting residues. In summary, this work presents a robust research strategy and offers valuable insights for identifying new c-Myc/Max disruptors.